

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

**Placing Agent
Cheong Lee Securities Limited**

The Board is pleased to announce that the condition of the Placing set out in the Placing Agreement had been fulfilled and Completion took place on 23 December 2025 in accordance with the terms and conditions of the Placing Agreement.

A total of 33,432,000 Placing Shares, representing approximately 16.66% of the issued share capital of the Company as at the date of this announcement immediately after Completion, have been placed to not less than six Placees at the Placing Price of HK\$0.225 per Placing Share. The net proceeds from the Placing are approximately HK\$7.4 million.

Reference is made to the announcement of New Ray Medicine International Holding Limited (“**Company**”) dated 5 December 2025 (the “**Announcement**”) in relation to the Placing. Capitalised terms used in this announcement shall have the same meanings as defined in the Announcement unless otherwise stated.

COMPLETION OF THE PLACING

The Board is pleased to announce that the condition of the Placing set out in the Placing Agreement had been fulfilled and Completion took place on 23 December 2025 in accordance with the terms and conditions of the Placing Agreement. A total of 33,432,000 Placing Shares, representing approximately 16.66% of the issued share capital of the Company as at the date of this announcement immediately after Completion, have been placed to not less than six Placees at the Placing Price of HK\$0.225 per Placing Share.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, (i) each of the Placees and where appropriate, their respective ultimate beneficial owners, is an Independent Third Party; and (ii) none of the Placees has become a substantial Shareholder immediately upon Completion.

The net proceeds from the Placing (after deduction of placing fee and other expenses of the Placing) are approximately HK\$7.4 million, which the Company intends to use the entire amount of the net proceeds arising from the Placing for the acquisition of additional distribution rights for the Group's core business.

EFFECTS ON SHAREHOLDING STRUCTURE OF THE COMPANY

Shareholders	Immediately before Completion		Immediately upon Completion	
	<i>No. of Shares</i>	<i>Approximate %</i>	<i>No. of Shares</i>	<i>Approximate %</i>
Eagle Amber Holdings Limited (<i>Note 1</i>)	42,667,200	25.52	42,667,200	21.27
Placees (<i>Note 2</i>)	–	–	33,432,000	16.66
Other public Shareholders	124,517,465	74.48	124,517,465	62.07
Total	167,184,665	100.00	200,616,665	100.00

Notes:

- Such 42,667,200 Shares are held by Eagle Amber Holdings Limited, which is beneficially owned as to 50.0% by Mr. Chu Xueping (an executive Director) and as to 50.0% by Mr. Dai Xiaosong. Accordingly, Mr. Chu Xueping and Mr. Dai Xiaosong are each deemed to be interested in the 42,667,200 Shares held by Eagle Amber Holdings Limited under Part XV of SFO.
- It is a term of the Placing Agreement that none of the Placees shall become a substantial shareholder of the Company upon Completion.
- Certain percentage figures included in this table have been subject to rounding adjustments. Accordingly, figures shown as totals may not be an arithmetic aggregation of the figures preceding them.

By order of the Board
New Ray Medicine International Holding Limited
Wang Qiuqin
Chairman & Executive Director

Hong Kong, 23 December 2025

As at the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Chu Xueping and Ms. Zhou Wan; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.